Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Lundbeck Urged to Do More to Stop Drug’s Use in Executions

June 17 (Bloomberg) -- Doctors who’ve prescribed medicines produced by H. Lundbeck A/S urged the Danish drugmaker to make more of an effort to stop the use of one of its treatments in executions of U.S. prisoners facing the death penalty.

“We are appalled at the inaction of Lundbeck to prevent the supply of their drug, Nembutal,” doctors from the U.K., Saudi Arabia, Denmark, India and the U.S. said in the June 18 issue of Lancet. Nembutal, also known as pentobarbital, “is rapidly proving to be the drug of choice for U.S. executions,” five doctors, writing on behalf of another 58 physicians, wrote in the medical journal.

The drug, first approved in 1939, is used to treat seizures and to euthanize animals. U.S. states, starting with Oklahoma in December, have begun administering the sedative to execute prisoners after facing a shortage of sodium thiopental. That drug’s manufacturer, Hospira Inc., stopped production after authorities in Italy, where manufacturing is located, asked for a guarantee it wouldn’t be used in executions. Italy doesn’t have the death penalty.

Writing in the Lancet, the doctors, led by David Nicholl, a U.K. neurologist, said Lundbeck should adopt measures similar to those it uses to control distribution of two other drugs, Sabril and Xenazine, for health reasons. Sabril is also used to treat seizures, while doctors prescribe Xenazine for patients with Huntington’s disease.

U.S. Prisons

Lundbeck, which has said it opposes the death penalty, sells 50 million doses of Nembutal a year in the U.S. Revenue from the drug makes up less than 1 percent of Lundbeck’s annual sales, which were 14.77 billion kroner ($2.84 billion) last year, spokesman Anders Schroll said.

Lundbeck has hired advisers to draw up a plan by September to make it more difficult for U.S. prisons to buy Nembutal, the Copenhagen-based company said today. Lundbeck may also take steps before September, Schroll said.

“We hope that such measures will make the prisons refrain from misusing the medicine,” Chief Executive Officer Ulf Wiinberg said in an e-mail. “However, we also realize that it is unlikely that we will be able to completely prevent state authorities from obtaining pentobarbital, even with significant restrictions on distribution.”

Lundbeck rose 1.40 kroner, or 1.1 percent, to 129.40 kroner in Copenhagen trading. The stock has gained 22 percent this year, compared with a gain of 2.9 percent in the Bloomberg Europe Pharmaceutical Index.

Lundbeck acquired Nembutal when it took over Deerfield, Illinois-based Ovation Pharmaceuticals Inc. in 2009.

Organizations opposing the death penalty, including Reprieve, have criticized the company for not doing more to stop the drug’s use in executions.

“If Lundbeck puts in tough controls, it would have very wide ramifications,” Maya Foa, an investigator with Reprieve, said by phone today.

To contact the reporter on this story: Frances Schwartzkopff in Copenhagen at

To contact the editor responsible for this story: Angela Cullen at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.